dOccLSNCT05953038
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain
StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment reopened Show 5 more changesShow less
- Lead sponsor: Rigshospitalet, Denmark to Copenhagen University Hospital, Rigshospitalet
- Eligibility criteria shortened, about 1 word
- Secondary endpoints: details revised at 4 of 5 entries
- Study description revised
- Site details revised
- Minor Primary completion date: Dec 18, 2027 to Dec 2027v4
- Notable Primary completion date: Jun 2024 to Dec 18, 2027
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Dec 2024 to Dec 31, 2027
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 1, 2023 to Nov 8, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation
Timeframe: Within 24 hours following drug administration
Secondary (5)
Subjective drug intensity - 5-HT2AR occupancy relation
fMRI network disintegration - 5-HT2AR occupancy relation
fMRI brain entropy - 5-HT2AR occupancy relation
Cerebral perfusion - 5-HT2AR occupancy relation
Administered LSD dose - 5-HT2AR occupancy relation
Arms and interventions
LSD dose-ranging groupExperimental
All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.
Drugs: Lysergic Acid Diethylamide Tartrate
Sites
1 site in 1 country
- Neurobiology Research Unit, RigshospitaletCopenhagen, Denmark